Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study

Journal of Clinical Oncology

Volumn 30, Issue 19, 2012, Pages 2362-2368

  Musolino, Antonino ^a   Michiara, Maria ^a   Conti, Giovanni Maria ^b   Boggiani, Daniela ^a   Zatelli, Marella ^b   Palleschi, Dario ^a   Bella, Maria Angela ^a   Sgargi, Paolo ^a   Di Blasio, Beatrice ^a   Ardizzoni, Andrea ^a  

^a UNIVERSITY HOSPITAL OF PARMA   (Italy)

^b Azienda Sanitaria Locale   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER SIZE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POPULATION RESEARCH; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; RECEPTOR, ERBB-2; REGISTRIES;

EID: 84864023283     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.6434     Document Type: Article

References (44)

1. US Preventive Services Task Force: Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 151:716-726, W-236, 2009
2. Nelson HD, Tyne K, Naik A, et al: Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med 151:727-737, W237-W242, 2009
3. Schroën AA, Wobbes T, van der Sluis RF: Interval carcinomas of the breast: A group with intermediate outcome. J Surg Oncol 63:141-144, 1996
4. Senie RT, Lesser M, Kinne DW, et al: Method of tumor detection influences disease-free survival of women with breast carcinoma. Cancer 73:1666-1672, 1994 (Pubitemid 24085267)
5. Frisell J, von Rosen A, Wiege M, et al: Interval cancer and survival in a randomized breast cancer screening trial in Stockholm. Breast Cancer Res Treat 24:11-16, 1992 (Pubitemid 23012688)
6. Holmberg LH, Tabar L, Adami HO, et al: Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 2:27-30, 1986 (Pubitemid 16063767)
7. Vitak B: Invasive interval cancers in the Ostergotland Mammographic Screening Programme: Radiological analysis. Eur Radiol 8:639-646, 1998
8. Brekelmans CT, Peeters PH, Deurenberg JJ, et al: Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 31A:1830-1835, 1995
9. Tabar L, Fagerberg G, Chen HH, et al: Screening for breast cancer in women aged under 50: mode of detection, incidence, fatality, and histology. J Med screen 2:94-98, 1995
10. Ikeda DM, Andersson I, Wattsgard C, et al: Interval carcinomas in the Malmo Mammographic Screening Trial: Radiographic appearance and prognostic considerations. AJR Am J Roentgenol 159:287-294, 1992
11. DeGroote R, Rush BF Jr, Milazzo J, et al: Interval breast cancer: A more aggressive subset of breast neoplasias. Surgery 94:543-547, 1983 (Pubitemid 13012174)
12. Porter PL, El Bastawissi AY, Mandelson MT, et al: Breast tumors characteristics as predictors of mammographic detection: Comparison of intervaland screen-detected cancers. J Natl Cancer Inst 91:2020-2028, 1999
13. Crosier M, Scott D, Wilson RG, et al: Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682-2688, 1999 (Pubitemid 29493939)
14. Gilliland FD, Joste N, Stauber PM, et al: Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743-749, 2000 (Pubitemid 30365535)
15. Pálka I, Kelemen G, Ormandi K, et al: Tumor characteristics in screen-detected and symptomatic breast cancers. Pathol Oncol Res 14:161-167, 2008
16. Collett K, Stefansson IM, Eide J, et al: A basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108-1112, 2005 (Pubitemid 40656455)
17. Kirsh VA, Chiarelli AM, Edwards SA, et al: Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 103:942-950, 2011
18. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987 (Pubitemid 17231334)
19. Kallioniemi OP, Holli K, Visakorpi T, et al: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
20. Istituto Nazionale di Statistica (ISTAT): Fourteenth population census, 2001 update. http://dawinci.istat.it/daWinci/jsp/MD/dawinciMD.jsp?a1= m0GG0C0I0&a2=mg0y8048F8&n=1UH90T09OG0&v=1UH08907U6301010000
21. Bucchi L, Falcini F, Baraldi GP, et al: Integrating self-referral for mammography into organised screening: Results from an Italian experience. J Med Screen 10:134-138, 2003 (Pubitemid 38296849)
22. Servizio Sanitario Regionale Emilia-Romagna: Cancer screening program 9, 2006 update. http://www.saluter.it/documentazione/rapporti/contributi/ contributi-n.-53-2008
23. Bucchi L, Ravaioli A, Foca F, et al: Incidence of interval breast cancers after 650,000 negative mammographies in 13 Italian health districts. J Med Screen 15:30-35, 2008 (Pubitemid 351629544)
24. Perry N, Broeders M, de Wolf C, et al: European guidelines for quality assurance in breast cancer screening and diagnosis: Fourth edition - Summary document. Ann Oncol 19:614-622, 2008 (Pubitemid 351461029)
25. Greene FL, Page DL, Fleming ID, et al: AJCC Cancer Staging Manual (ed 6). New York, NY, Springer, 2002, pp 223-228
26. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer: I - The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 19: 403-410, 1991
27. Bozzetti C, Musolino A, Personeni N, et al: Correlation between HER-2/neu amplification in fine needle aspirates from breast carcinoma and response to neoadjuvant anthracycline-based chemotherapy. Am J Clin Oncol 29:171-177, 2006 (Pubitemid 44270959)
28. Dowsett M, Nielsen TO, A'hern R, et al: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst 103:1656-1664, 2011
29. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007 (Pubitemid 350003059)
30. American College of Radiology. American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) (ed 4). Reston, VA, American College of Radiology, 2003, pp 253-259
31. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748, 1959
32. Freeman DH. Applied Categorical Data Analysis. New York, NY, Marcel Dekker, 1987, pp 618-621
33. Joensuu H, Asola R, Holli K, et al: Delayed diagnosis and large size of breast cancer after a false negative mammogram. Eur J Cancer 30A:1299-1302, 1994 (Pubitemid 24322066)
34. Kerlikowske K, Grady D, Barclay J, et al: Effect of age, breast density, and family history on the sensitivity of first screening mammography. JAMA 276:33-38, 1996 (Pubitemid 26231053)
35. Rosenberg RD, Hunt WC, Williamson MR, et al: Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis: Review of 183,134 screening mammograms in Albuquerque, New Mexico, 1991 to 1993. Cancer 78:1731-1739, 1996
36. Ma L, Fishell E, Wright B, et al: Case-control study of factors associated with failure to detect breast cancer by mammography. J Natl Cancer Inst 84:781-785, 1992
37. Burhenne HJ, Burhenne LW, Goldberg F, et al: Interval breast cancers in the Screening Mammography Program of British Columbia: Analysis and classification. AJR Am J Roentgenol 162:1067-1071; discussion 1072-1075, 1994
38. Domingo L, Sala M, Servitja S, et al: Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 21:1155-1164, 2010
39. Foulkes WD, Stefansson IM, Chappuis PO, et al: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485, 2003 (Pubitemid 37279334)
40. Komenaka IK, Ditkoff BA, Joseph KA, et al: The development of interval breast malignancies in patients with BRCA mutations. Cancer 100:2079-2083, 2004 (Pubitemid 38580324)
41. Koivunen D, Zhang X, Blackwell C, et al: Interval breast cancers are not biologically distinct - Just more difficult to diagnose. Am J Surg 168:538-542, 1994 (Pubitemid 24378514)
42. Anttinen J, Kuopio T, Nykanen M, et al: Her- 2/neu oncogene amplification and protein overexpression in interval and screen-detected breast cancers. Anticancer Res 23:4213-4218, 2003 (Pubitemid 37474922)
43. Sihto H, Lundin J, Lehtimäki T, et al: Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res 14:4103-4110, 2008
44. Bulliard JL, Sasieni P, Klabunde C, et al: Methodological issues in international comparison of interval breast cancers. Int J Cancer 119:1158-1163, 2006 (Pubitemid 44116926)